Single center, phase II, open label randomized clinical trial to evaluate the inhibition of ovulation of three prolonged release formulations containing a combination of Dienogest and Ethinyl Estradiol versus a flexible regimen contraceptive containing drospirenone 3mg and Ethinyl Estradiol 20µg in 100 healthy women.
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
Price : $35 *
At a glance
- Drugs Ethinylestradiol/dienogest (Primary) ; Drospirenone/ethinylestradiol
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Exeltis
- 21 Feb 2018 Status changed from recruiting to completed.
- 01 Mar 2017 New trial record